263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019) - McInnes, Iain B; Deodhar, Atul; Gladman, Dafna D; Ren, Mengyuan; Spindeldreher, Sebastian; Pricop, Luminita; Porter, Brian; Safi, Jorge; Shete, Abhijit; Bruin, Gerard